ClinicalTrials.Veeva

Menu

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Pfizer logo

Pfizer

Status and phase

Enrolling
Phase 4

Conditions

Solid Tumors

Treatments

Drug: Binimetinib
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Irinotecan
Drug: 5-Fluorouracil
Drug: Vemurafenib
Biological: Nivolumab
Drug: Leucovorin
Drug: Encorafenib
Drug: Ribociclib
Biological: Cetuximab
Biological: Bevacizumab
Biological: Pembrolizumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT05203172
C4221026
2023-509408-13-00 (Registry Identifier)
FLOTILLA (Other Identifier)
2023

Details and patient eligibility

About

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib.

All participants who took part in earlier encorafenib and/or binimetinib studies may participate in the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they were not enrolled in a prior study of encorafenib or binimetinib.

Participants who had enrolled but had stopped receiving the study treatment in a prior study cannot be enrolled in this study. Participants in the FLOTILLA study will receive study treatment at the same dose and frequency as in their prior study, for up to about 5 years.

Full description

This is an open-label, continuation study for participants receiving study intervention(s) in an encorafenib/binimetinib Parent Study. The study is being conducted under a Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies, with individual encorafenib/binimetinib continuation sub-study protocols that cover each eligible Parent Study. Up to approximately 210 participants from qualifying Parent Studies will be included in this Encorafenib/Binimetinib Continuation study.

This continuation study includes multiple sub-study protocols to allow participants from each of the following Parent Studies: C4211001 - NCT01320085; C4211003 - NCT01849874; C4221003 - NCT03864042; C4221004 - NCT01909453; C4221005 - NCT01543698; C4221006 - NCT03911869; C4221008 - NCT03915951; C4221009 - NCT02928224; C4221010 - NCT01436656; C4221013 - NCT02159066; ANCHOR-CRC - NCT03693170; C4221015 - NCT04607421; C4221016 - NCT04657991; C4221022 - NCT05217446; C4221023 - NCT05926960

Enrollment

210 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any participant who is receiving study intervention and deriving clinical benefit (as determined by the principal investigator) in an encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03 Grade ≥3 or intolerable Grade 2 AEs considered to be related to study treatment.
  • Participants must agree to follow the reproductive criteria as outlined in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol.

Exclusion criteria

- Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

210 participants in 9 patient groups

Sub-Study C4221004C
Experimental group
Description:
Continued treatment access for participants from the C4221004 (ARRAY CMEK162B2301, COLUMBUS) Encorafenib and Binimetinib study. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Drug: Encorafenib
Drug: Vemurafenib
Drug: Binimetinib
Sub-Study C4221005C
Experimental group
Description:
Continued treatment access for participants from the C4221005 (ARRAY CMEK162X2110) Encorafenib and Binimetinib study. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Drug: Ribociclib
Drug: Encorafenib
Drug: Binimetinib
Sub-Study C4211001C / C4211003C
Experimental group
Description:
Continued treatment access for participants from the C4211001 (ARRAY CMEK162×2201) and the C4211003 (ARRAY-162-311, MILO) Binimetinib studies. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Drug: Binimetinib
Sub-Study C4221003C / C4221006C / C4221013C
Experimental group
Description:
Continued treatment access for participants from the C4221003 (ARRAY-818-103), C4221006 (ARRAY-818-201) and the C4221013 (ARRAY CLGX818X2109) Encorafenib and Binimetinib studies. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Drug: Encorafenib
Drug: Binimetinib
Sub-Study C4221009C / W00090 GE 2 01C
Experimental group
Description:
Continued treatment access for participants from the C4221009 (ARRAY-818-302, BEACON) and W00090 GE 2 01 (ANCHOR CRC) Encorafenib, Binimetinib and Cetuximab studies. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Biological: Cetuximab
Drug: Encorafenib
Drug: Binimetinib
Sub-Study C4221008C
Experimental group
Description:
Continued treatment access for participants from the C4221008 (ARRAY-818-202, PHAROS) Encorafenib and Binimetinib study. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Drug: Encorafenib
Drug: Binimetinib
Sub-Study C4221016C / C4221023C
Experimental group
Description:
Continued treatment access for participants from the C4221016 (STARBOARD) and C4221023 (PORTSIDE) Encorafenib and Binimetinib studies. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Biological: Pembrolizumab
Drug: Encorafenib
Biological: Nivolumab
Drug: Binimetinib
Sub-Study C4221010C
Experimental group
Description:
Continued treatment access for participant from the C4221010 (CLGX818X2101) Encorafenib study. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Drug: Encorafenib
Sub-Study C4221015C / C4221022C
Experimental group
Description:
Continued treatment access for participants from the C4221015 (BREAKWATER) and C4221022 (SEAMARK) Encorafenib studies. Each participant will receive the same study treatment as received in the Parent Study.
Treatment:
Biological: Bevacizumab
Biological: Cetuximab
Drug: Encorafenib
Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: Irinotecan
Drug: Oxaliplatin

Trial contacts and locations

77

Loading...

Central trial contact

Pfizer CT.gov Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems